Freenome Inc FRNM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
-
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
-
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
-
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
Trading Information
- Previous Close Price
- $13.10
- Day Range
- $12.48–13.13
- 52-Week Range
- $9.95–17.50
- Bid/Ask
- $12.80 / $13.84
- Shares Outstanding
- 107.45M
- Market Cap
- $1.37B
- Volume/Avg
- 612,770 / 863,815
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 45.19
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Freenome Inc is a development-stage, early cancer detection company developing blood-based screening tests leveraging a proprietary artificial intelligence/machine learning multiomics technology platform to transform multi-cancer and ultimately multi-disease detection. It is developing a range of blood-based cancer screening tests.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.freenome.com
Valuation
|
Metric
|
FRNM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 45.19 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FRNM
|
|---|---|
Quick Ratio | 5.38 |
Current Ratio | 5.59 |
Interest Coverage | −79.23 |
Quick Ratio
FRNM
Profitability
|
Metric
|
FRNM
|
|---|---|
Return on Assets (Normalized) | −39.39% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
FRNM
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|x&k&Qfh | LOCK|D% | $249B | |||
| Danaher Corp
DHR
| LOCK|rPV?CsTM | LOCK|S> | $162B | |||
| Agilent Technologies Inc
A
| LOCK|mV@^RDl | LOCK|sV | $49B | |||
| IQVIA Holdings Inc
IQV
| LOCK|m!^$G^P | LOCK|!v>^Q | $46B | |||
| Waters Corp
WAT
| LOCK|P&F$!?% | LOCK|xnq | $45B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|&%&w$G>! | LOCK|b<s | $44B | |||
| Illumina Inc
ILMN
| LOCK|?#yqnbS | LOCK|vGKz | $41B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|@Y>Q%>vy | LOCK|tnX!f | $33B | |||
| Quest Diagnostics Inc
DGX
| LOCK|^FdtSN | LOCK|fXQYJ | $27B | |||
| Labcorp Holdings Inc
LH
| LOCK|Mq!L?l# | LOCK|Kggt | $27B |
United States